Total Knee ArthroplastyRevision Total Knee Arthroplasty
Investigational drug(s) / intervention(s)
Multigen Plus CCKAMF TT cones
Multigen Plus CCK: Total Knee Arthroplasty
AMF TT cones: To fill a proximal tibia or distal femur defect
Study summary
This study is aimed to provide a clinical and radiographic evaluation of 68 condylar-constrained Total Knee Arthroplasty (TKA) using a single type of prosthesis (Multigen Plus CCK configuration), alone or involving the AMF TT cones, in patients with joint instability or inadequate ligament function, both in complex primary and revision procedures.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Male or female.
* Age ≥ 18 years old.
* Given written informed consent approved by the reference Ethics Committee (EC).
* Subjects in whom a decision has already been made to perform a Total Knee Arthroplasty with Multigen Plus system as per Indication For Use. The decision to implant a Multigen Plus CCK system, alone or involving the AMF TT cones, must be taken prior to, and independently from, the decision to enrol the subject. This decision should be made in accordance with routine clinical practice at the study site concerned.
* Subjects able to comply with the Study Protocol.
Exclusion Criteria:
* Age \< 18 years old.
* Subjects with any Multigen Plus system contraindication for use, or any AMF TT cones contraindication for use when used in combination with the Multigen Plus CCK, as reported in the current Instruction For Use.
* Any clinically significant pathology based on the medical history that the Investigator feels may affect the study evaluation.
* Female subjects who are pregnant, nursing, or planning a pregnancy.
* Previous knee replacement on the contralateral side within the last year and whose outcome is achieving an KSS \< 70 points.
Primary outcome measure(s)
Knee Society Score (KSS) — Month 24 Functional changes in the Knee Society Score (KSS) from pre-operative (baseline) to 2 years after the surgery.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.